end stage knee osteoarthritis
Conditions
Interventions
a. 4 weeks no treatment
b. 4 weeks 2x daily 200 mg celecoxib/Celebrex until the surgery
c. 4 weeks 2x daily 200 mg celecoxib/Celebrex until 3 days before surgery
d. 4 weeks 3x daily 250 mg.
Naproxen/Aleve until 3 days before surgery.
Sponsors
Sint Franciscus Gasthuis hospital Rotterdam
Eligibility
Inclusion criteria
Inclusion criteria: Patients with knee osteoarthritis eligible for and on the waiting list for total knee replacement surgery at the Sint Fransiscus Gasthuis hospital in Rotterdam.
Exclusion criteria
Exclusion criteria: 1. Patients who are eligible for a total knee replacement operation for other reasons than OA; 2. Patients with an increased risk for gastro-intestinal bleeding; 3. Patients with an increased risk of cardio-vascular disease such as a history of cardio-vascular disease like myocardium infarct, heart failure, CVA and TIA; 4. Patients with untreated/insufficiently treated hypertension; 5. Patients with angina pectoris and patients on oral anticoagulants; 6. Patients with serious liver and/or kidney function impairment; 7. Patients with intolerance for naproxen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in proteoglycan release of the OA cartilage under the influence of celecoxib. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in several biochemical and histochemical characteristics of the OA cartilage including proteoglycan synthesis rate, proteoglycan content, prostaglandin E2 production, and COX-1 and COX-2 expression of cartilage. | — |
Contacts
Public ContactT.N. Boer, de
UMC Utrecht PO Box 85500, F02.127
Outcome results
None listed